Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit

This article was originally published in The Gray Sheet

  • News

Executive Summary

Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business

You may also be interested in...



Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy

Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology

Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy

Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology

ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI

ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT016711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By